Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer

Ameri, A; Tavakoli-Far, B; Rostami, M; Kiasari, BA; Sakhaei, D; Ahmed, OS; Forouzani, F; Fazli, Y

Forouzani, F (通讯作者),Yasuj Univ Med Sci, Sch Med, Yasuj, Iran.;Fazli, Y (通讯作者),Alborz Univ Med Sci, Student Res Comm, Alborz, Iran.

INTERNATIONAL IMMUNOPHARMACOLOGY, 2022; 113 ():

Abstract

Breast cancer, the most common cancer in women worldwide, is curable in - 70-80 % of patients with early-stage, non-metastatic disorder. However, adva......

Full Text Link